A Prospective 3-Year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study With a TMC435-Containing Regimen for the Treatment of Hepatitis C Virus (HCV) Infection.
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Janssen R&D Ireland
- 19 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 06 Dec 2013 Planned End Date changed from 1 May 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 24 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.